There is provided a fluorine-containing ether compound represented by following formula: R.sup.1R.sup.2CH.sub.2R.sup.3[CH.sub.2R.sup.4CH.sub.2R.sup.3].sub.nCH.sub.2R.sup.5R.sup.6 (n is 1 or 2; R.sup.3 and R.sup.3 are a perfluoropolyether chain; R.sup.4 is a divalent linking group having one polar group; R.sup.2 and R.sup.5 are a divalent linking group having one or more polar groups; R.sup.2 has an oxygen atom at an end that is bonded to R.sup.1; R.sup.5 has an oxygen atom at an end that is bonded to R.sup.6; R.sup.1 and R.sup.6 in end group bonded to an oxygen atom at an end of R.sup.2 or R.sup.5; and R.sup.1 and R.sup.6 are an organic group having 1 to 50 carbon atoms, and at least one of them is a group in which a carbonyl carbon atom or nitrogen atom constituting an amide bond is bonded to a carbon atom of an organic group having 1 to 8 carbon atoms).

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]: ##STR00001##
wherein R is H, C.sub.1-4 alkyl or phenyl; R.sup.2 is (CH.sub.2).sub.m wherein m is between 0 and 4; R.sup.3 and R.sup.4 are each independently H or C.sub.1-4 alkyl, R.sup.5 is or OH, R.sup.6 is selected from a group consisting of: amide and alkyl, and R.sup.7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

To provide a fluorinated compound capable of obtaining a cured product which is excellent in heat resistance and mold release and has a high Abbe number; a curable composition containing such a compound; and a cured product which is excellent in heat resistance and mold release and has a high Abbe number. The fluorinated compound is represented by the following formula (A):

[ZOCH.sub.2CF.sub.2CF.sub.2CF.sub.2OCFHCF.sub.2X-].sub.nQ(A)

where n is an integer of at least 1, Q is a n-valent organic group, X is O, NH or S, and Z is a group having at least one polymerizable functional group.

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]:

##STR00001##

wherein R is H, C.sub.1-4 alkyl or phenyl; R.sup.2 is (CH.sub.2).sub.m wherein m is between 0 and 4; R.sup.3 and R.sup.4 are each independently H or C.sub.1-4 alkyl, R.sup.5 is or OH, R.sup.6 is selected from a group consisting of: amide and alkyl, and R.sup.7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]: ##STR00001##
wherein R is H, C.sub.1-4 alkyl or phenyl; R.sup.2 is (CH.sub.2).sub.m wherein m is between 0 and 4; R.sup.3 and R.sup.4 are each independently H or C.sub.1-4 alkyl, R.sup.5 is H or OH, R.sup.6 is selected from a group consisting of: amide and alkyl, and R.sup.7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]:

##STR00001##

wherein R is H, C.sub.1-4 alkyl or phenyl; R.sup.2 is (CH.sub.2).sub.m wherein m is between 0 and 4; R.sup.3 and R.sup.4 are each independently H or C.sub.1-4 alkyl, R.sup.5 is H or OH, R.sup.6 is selected from a group consisting of: amide and alkyl, and R.sup.7 is a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

An ionic lubricant includes a single lubricant compound having a perfluoropolyether main chain, wherein each end of the perfluoropolyether main chain is terminated by an end group, and at least one of the end groups includes an ionic bond and at least one functional group. The ionic perfluoropolyether lubricant has unique characteristics that allows its ultra-thin and uniform distribution over a protective overcoat layer of a magnetic recording medium, while at the same time providing its molecules with strong adhesion power to the protective overcoat layer of the magnetic recording medium compared to existing lubricants, so as to provide shorter magnetic spacing between the magnetic recording medium and the magnetic head, and enable longer operation hours for the magnetic recording medium.

The present invention relates to a composition comprising a mixture of a first and a second hydrophobically modified alkylene oxide polymer, wherein the first hydrophobically modified alkylene oxide polymer is endcapped with at least one first hydrophobic group functionalized with a secondary amine or a salt thereof, or a tertiary amine or a salt thereof; and wherein the second hydrophobically modified alkylene oxide polymer is endcapped with at least one second hydrophobic group, structure I: ##STR00001##
where R.sup.1, R.sup.2, m, and n are as defined herein. The present invention also relates to a method for preparing the composition. The composition of the present invention provides an associative thickener with an excellent balance of as-is viscosity and temperature stability over a wide temperature range.

A method for producing a high molecular weight polyoxyethylene derivative having a derivatized hydroxyl group is disclosed. The method includes labeling an unreacted high molecular weight polyoxyethylene compound having a hydroxy group using a labeling reagent in a deuterated solvent, and quantitating a labeled solution by a pre-saturation method and a proton nuclear magnetic resonance spectroscopy using inverse gated decoupling. The method allows a prompt quantitation of unreacted high molecular weight polyoxyethylene compound having a hydroxy group with a high accuracy.

The present invention discloses a non-linear PEGylated lipid, including the structure represented by the Formula (1); wherein, B.sub.1 and B.sub.2 are linking bonds or alkylene groups; L.sub.1 and L.sub.2 are linking bonds or divalent linking groups; L.sub.x, Y, and L.sub.d are divalent linking groups; R.sub.1 and R.sub.2 are C.sub.4-50 hydrocarbon groups or C.sub.4-50 residues of hydrocarbon derivative containing 1-4 heteroatoms; X is CH< or

##STR00001##

n.sub.1, n.sub.2, and n.sub.3 are integers in the range of 4-250; T is a terminal group. Compared with linear PEGylated lipids, the non-linear PEGylated lipid provided herein can realize better protective effects toward the modified LNPs. The lipid pharmaceutical composition of the present invention exhibits high efficiency of drug encapsulation, appropriate particle size, non-toxicity, and good stability in serum. The LNP-nucleic acid pharmaceutical composition of the present invention demonstrates an excellent ability to complex with nucleic acids and shows high transfection activity.

##STR00002##